XML 41 R27.htm IDEA: XBRL DOCUMENT v3.26.1
STOCKHOLDERS’ EQUITY (DEFICIENCY) (Tables)
 9 Months Ended
Mar. 31, 2026
Equity [Abstract]  
SCHEDULE OF WARRANT EXERCISES
       Three Months Ended March 31, 2026   Nine Months Ended March 31, 2026 
Series  Exercise Price   Warrants   Proceeds   Warrants   Proceeds 
Series F Warrants  $15.00    -   $-    16,866   $252,990 
Series G Warrants  $7.50    3,168    23,760    79,092    593,197 
Series H Warrants  $11.25    900    10,125    31,499    354,364 
Series J Warrants  $6.50    10,000    65,000    29,984    194,896 
Series K Warrants  $8.125    5,000    40,625    24,984    202,994 
         19,068   $139,510    182,425   $1,598,441 
SCHEDULE OF OUTSTANDING STOCK PURCHASE WARRANTS

As of March 31, 2026, the Company had outstanding warrants for shares of common stock as follows:

 

   Shares of Common   Exercise Price per   Latest Expiration
Description  Stock   Share   Date
May 2022 Warrants   1,333   $625.00   May 11, 2026
October 2022 Placement Agent Warrants   1,818   $10.00   October 31, 2027
October 2023 Placement Agent Warrants   2,358   $10.00   October 20, 2028
January 2024 Private Warrants   36,630   $273.00   February 1, 2028
January 2024 Placement Agent Warrants   1,831   $10.00   February 1, 2028
June 2024 Series B Warrants   37,712   $94.00   July 25, 2030*
December 2024 Series C Warrants   78,153   $43.75   December 17, 2029
December 2024 Series D Warrants   39,076   $43.75   July 25, 2030
February 2025 Series E Warrants   93,760   $50.00   August 12, 2030
May 2025 Series F Warrants   129,613   $15.00   May 8, 2030
May 2025 Series G Warrants   67,387   $7.50   May 8, 2027
May 2025 Series H Warrants   47,593   $11.25   -**
June 2025 Series I Warrants   123,636   $5.50   July 25, 2030
November 2025 Pre-funded Warrants   2,136,000   $0.0001   N/A
November 2025 Series J Warrants   2,765,400   $6.50   -***
November 2025 Series K Warrants   2,770,400   $8.13   -****
November 2025 Placement Agent Warrants   55,907   $8.13   November 12, 2030
November 2025 HCW Settlement Warrants   10,000   $10.00   January 12, 2028

 

*5,228 warrants expire June 24, 2029

 

**Expire 24 months following the intial exercise date

 

***Expires the earlier of (i) the 18-month anniversary of the Initial Exercise Date if FDA IND acceptance has not been received, or (ii) 31 days after notice of FDA IND acceptance, in each case adjusted to the next Trading Day; provided that under clause (ii) the date is extended until a registration statement and prospectus are available for 30 consecutive days.

 

****Expire on the 5-year anniversary of the Initial Exercise Date, or, if the Holder’s Series J Common Stock Purchase Warrant terminates pursuant to clause (ii) thereof prior to full cash exercise, the same Termination Date as the Series J Warrant, in each case adjusted to the next Trading Day; provided that the date is extended until a registration statement and prospectus are available for 30 consecutive days following notice of FDA IND acceptance.
SCHEDULE OF STOCK OPTION ACTIVITY

A summary of stock option activity is as follows:

 

   Number of Shares   Weighted Average Exercise Price   Weighted Average Remaining Term in Years   Aggregate Intrinsic Value 
                 
Outstanding - June 30, 2025   44,805   $302.00    7.3      
                     
Granted   39,550    21.38           
Fractional shares   (14)               
Forfeited   (1,266)   76.33           
Exercised   -    -           
Expired   (4,497)   480.12           
Outstanding - March 31, 2026   78,578   $159.01    8.1   $- 
                     
Exercisable at March 31, 2026   24,307   $407.50    5.8   $- 
                     
Expected to vest at March 31, 2026   54,271   $46.53    9.2   $- 
SCHEDULE OF RESTRICTED STOCK UNITS ACTIVITY

A summary of RSU activity is as follows:

 

Outstanding at June 30, 2025   22,787 
Granted   24,950 
Forfeited   - 
Vested   (6,467)
Expirations   (1,254)
Fractional shares   - 
Outstanding at March 31, 2026   40,016